Differential antiviral effects of pegylated interferon-α2a and pegylated interferon-α2b in chronic hepatitis C.

Abstract:

BACKGROUND AND OBJECTIVES:Pegylated interferon (peg-IFN)-α2a and -α2b show different pharmacokinetic properties but are used interchangeably for hepatitis C treatment in traditional dual combinations and with newer agents. We assessed whether peg-IFN antiviral effects vary with peg-IFN subtype, affecting viral response in a differential manner. METHODS:Chronic hepatitis C patients treated with ribavirin combined with peg-IFN-α2a (N = 109) or -α2b (N = 114) were studied. Hepatitis C virus RNA quantitation was performed by Cobas TaqMan 5 min before treatment start and subsequently after 48/72 h and 7, 14, 28 and 90 days. Antiviral effect was assessed in terms of viraemia changes over treatment. Histology grading and staging, interleukin-28B (IL28B) status and baseline viral genotype, alanine aminotransferase, gamma glutamyltransferase and glucose were analysed. RESULTS:Viraemia decline after 48/72 h and 7 days was significantly greater with peg-IFN-α2b (1.96 and 2.12 vs 1.49 and 1.20 log10 IU/mL with peg-IFN-α2a; p < 0.001). Differences were of larger extent in patients with advanced fibrosis (p = 0.002), genotype 1 infection (p = 0.002) and CT/TT genotypes of IL28B (p = 0.001). A rebound in viral load was observed significantly more often after the first dose in patients treated with peg-IFN-α2b (78 vs 28 % in those with peg-IFN-α2a; p = 0.0001). Differences between peg-IFNs disappeared by day 28 of treatment. CONCLUSION:There are significant pharmacodynamic differences between peg-IFN-α2a and -α2b in the early phase of chronic hepatitis C treatment. The greater early viral decline observed with peg-IFN-α2b was essentially confined to 'difficult to treat' patients. Whether this could affect response-guided treatment decision making, as well as triple drug regimens, needs to be assessed.

journal_name

Clin Drug Investig

authors

Durante-Mangoni E,Parrella A,Iossa D,Andini R,Molaro R,Battimelli C,Sodano G,Utili R

doi

10.1007/s40261-014-0241-y

subject

Has Abstract

pub_date

2014-12-01 00:00:00

pages

871-8

issue

12

eissn

1173-2563

issn

1179-1918

journal_volume

34

pub_type

杂志文章
  • Safety of Overnight Switch from Brand-Name to Generic Levetiracetam.

    abstract:BACKGROUND AND OBJECTIVE:Concerns that antiepileptic brand-to-generic interchange results in disruption of seizure control are widespread. The objective of this study was to evaluate the safety and tolerability of the brand-to-generic levetiracetam switch in patients with focal or generalized epilepsy. METHODS:A prosp...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.1007/s40261-015-0351-1

    authors: Vari MS,Pinto F,Mencaroni E,Giudizioso G,Minetti C,La Neve A,Francavilla T,Piccioli M,Striano S,del Gaudio L,Tovo P,Striano P,Verrotti A

    更新日期:2016-01-01 00:00:00

  • Observational study of intravenous lacosamide in patients with convulsive versus non-convulsive status epilepticus.

    abstract:BACKGROUND AND OBJECTIVES:Status epilepticus (SE) is an important emergency situation associated with high morbidity and mortality. The goal of pharmacological therapy-rapid seizure termination-is only achieved in just over half of patients with first-line anti-epileptic drug (AED) therapy and many patients require sec...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.1007/s40261-015-0295-5

    authors: Moreno Morales EY,Fernandez Peleteiro M,Bondy Peña EC,Domínguez Lorenzo JM,Pardellas Santiago E,Fernández A

    更新日期:2015-07-01 00:00:00

  • Olmesartan medoxomil plus amlodipine increases efficacy in patients with moderate-to-severe hypertension after monotherapy: a randomized, double-blind, parallel-group, multicentre study.

    abstract:BACKGROUND AND OBJECTIVE:Hypertension remains a major global health problem, and evidence suggests that the majority of patients will require two or more antihypertensive agents in order to reach specified BP targets. Combining two drugs from different classes has the potential to target different aspects of hypertensi...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.2165/00044011-200929070-00001

    authors: Barrios V,Brommer P,Haag U,Calderón A,Escobar C

    更新日期:2009-01-01 00:00:00

  • α1-Proteinase inhibitor (human) in the treatment of hereditary emphysema secondary to α1-antitrypsin deficiency: number and costs of years of life gained.

    abstract:BACKGROUND:α(1)-Antitrypsin deficiency (α-ATD) is a disorder inherited in an autosomal recessive pattern, with co-dominant alleles known as the protease inhibitor system (Pi). The main function of α(1)-antitrypsin (α-AT) is to protect the lungs against a powerful elastase released from neutrophil leucocytes. α-ATD typi...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.2165/11631920-000000000-00000

    authors: Sclar DA,Evans MA,Robison LM,Skaer TL

    更新日期:2012-05-01 00:00:00

  • Clinical experience with lamotrigine monotherapy in adults with newly diagnosed epilepsy: a review of published randomised clinical trials.

    abstract:OBJECTIVES:This paper aimed to provide an overview from published randomised clinical trials of the efficacy and tolerability of lamotrigine monotherapy compared with carbamazepine and phenytoin when initiated in adult patients with newly diagnosed epilepsy. DESIGN:The review included two double-blind, randomised tria...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.2165/00044011-199816020-00005

    authors: Mullens EL

    更新日期:1998-01-01 00:00:00

  • Relative Bioavailability of Two Enteric-Coated Formulations of Omeprazole following Repeated Doses in Healthy Volunteers.

    abstract:OBJECTIVE:This study aimed to investigate the relative bioavailability and bioequivalence of two omeprazole enteric-coated formulations following repeated doses (steady state) in healthy male and female adult volunteers. DESIGN AND STUDY PARTICIPANTS:The study formulation (Ompranyt® 20mg capsules, Bial-Industrial Farm...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.2165/00044011-200121030-00006

    authors: Vaz-da-Silva M,Hainzl D,Almeida L,Dolgner A,Silveira P,Maia J,Soares-da-Silva P

    更新日期:2001-03-01 00:00:00

  • Pharmacokinetic-pharmacodynamic relationship of dobutamine and heart rate, stroke volume and cardiac output in healthy volunteers.

    abstract:BACKGROUND AND OBJECTIVE:Dobutamine causes an increase in cardiac output (CO) by augmenting stroke volume (SV) through enhanced left ventricular contractility and by decreasing systemic vascular resistance. However, in some patients, the dominant mechanism by which dobutamine improves left ventricular performance is an...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章,随机对照试验

    doi:10.2165/00044011-200828020-00006

    authors: Ahonen J,Aranko K,Iivanainen A,Maunuksela EL,Paloheimo M,Olkkola KT

    更新日期:2008-01-01 00:00:00

  • Oral Teicoplanin as an Alternative First-Line Regimen in Clostridium difficile Infection in Elderly Patients: A Case Series.

    abstract:BACKGROUND:Elderly patients are more susceptible to Clostridium difficile infections (CDIs). Despite existing guidelines, there is no specific treatment for CDI in geriatrics. Vancomycin is commonly used in the treatment of CDI. Teicoplanin is an alternative glycopeptide which recently received marketing authorization ...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.1007/s40261-017-0524-1

    authors: Davido B,Leplay C,Bouchand F,Dinh A,Villart M,Le Quintrec JL,Teillet L,Salomon J,Michelon H

    更新日期:2017-07-01 00:00:00

  • Dose Proportionality and Pharmacokinetics of Fentanyl Buccal Soluble Film in Healthy Subjects : A Phase I, Open-Label, Three-Period, Crossover Study.

    abstract:BACKGROUND AND OBJECTIVES:Fentanyl buccal soluble film (FBSF) is a small, bilayered, water-soluble polymer film (BioErodible MucoAdhesive; BEMA™) that adheres to the buccal mucosa and rapidly delivers fentanyl into the systemic circulation. It is approved for the treatment of cancer breakthrough pain in adult opioid-to...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.2165/11594670-000000000-00000

    authors: Finn AL,Vasisht N,Stark JG,Gever LN,Tagarro I

    更新日期:2012-01-01 00:00:00

  • Cost-Utility Analysis of Three Iron Chelators Used in Monotherapy for the Treatment of Chronic Iron Overload in β-Thalassaemia Major Patients: An Italian Perspective.

    abstract:PURPOSE:Deferiprone (DFP), deferasirox (DFX) and deferoxamine (DFO) are used in thalassaemia major (TM) patients to treat chronic iron overload. We evaluated the cost-effectiveness of DFP, compared with DFX and DFO monotherapy, from an Italian healthcare system perspective. METHODS:A Markov model was used over a time ...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.1007/s40261-017-0496-1

    authors: Pepe A,Rossi G,Bentley A,Putti MC,Frizziero L,D'Ascola DG,Cuccia L,Spasiano A,Filosa A,Caruso V,Hanif A,Meloni A

    更新日期:2017-05-01 00:00:00

  • Oxycodone controlled-release as first-choice therapy for moderate-to-severe cancer pain in Italian patients: results of an open-label, multicentre, observational study.

    abstract:BACKGROUND AND OBJECTIVES:Cancer pain affects patients at all stages of the disease and there are clear guidelines for its management. Morphine is considered the first-choice strong opioid in the treatment of moderate-to-severe pain; however, numerous studies have shown that oxycodone controlled-release (CR) has a simi...

    journal_title:Clinical drug investigation

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.2165/00044011-200828070-00001

    authors: Silvestri B,Bandieri E,Del Prete S,Ianniello GP,Micheletto G,Dambrosio M,Sabbatini G,Endrizzi L,Marra A,Aitini E,Calorio A,Garetto F,Nastasi G,Piantedosi F,Sidoti V,Spanu P

    更新日期:2008-01-01 00:00:00

  • Linguistic adaptation and validation of the Spanish version of the Benign Prostatic Hyperplasia-Patient Impact Measure (BPH-PIM).

    abstract:BACKGROUND:The Benign Prostatic Hyperplasia-Patient Impact Measure (BPH-PIM) is a self-reported quality-of-life questionnaire for measuring the impact of urinary/prostate symptoms on the quality of life of patients with BPH. The aim of the present study was to adapt the original instrument to Spanish (for use in Spain)...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.2165/00044011-200626020-00005

    authors: Llorente C,Ruiz M,Rejas Gutiérrez J,Esteban M,Villasante F,Hareendran A

    更新日期:2006-01-01 00:00:00

  • Determining clinically important changes in range of motion in patients with Dupuytren's Contracture: secondary analysis of the randomized, double-blind, placebo-controlled CORD I study.

    abstract:BACKGROUND AND OBJECTIVE:Injectable collagenase Clostridium histolyticum is efficacious in correcting Dupuytren's contracture as assessed by changes in the angle of contracture and range of motion (ROM). However, clinically important changes in ROM have not been evaluated in depth. The objective of this secondary analy...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/BF03256918

    authors: Witthaut J,Bushmakin AG,Gerber RA,Cappelleri JC,Le Graverand-Gastineau MP

    更新日期:2011-11-01 00:00:00

  • Drug interactions with levothyroxine therapy in patients with hypothyroidism: observational study in general practice.

    abstract:BACKGROUND AND OBJECTIVES:Several drugs may interact with levothyroxine and reduce its bioavailability. The aim of this study was to analyse the Italian general practice patients with hypothyroidism from 2002-2011, in terms of variation of thyroid-stimulating hormone (TSH) levels, number of levothyroxine prescriptions ...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.1007/s40261-015-0271-0

    authors: Trifirò G,Parrino F,Sultana J,Giorgianni F,Ferrajolo C,Bianchini E,Medea G,Benvenga S,Cricelli I,Cricelli C,Lapi F

    更新日期:2015-03-01 00:00:00

  • Ambroxol lozenge bioavailability : an open-label, two-way crossover study of the comparative bioavailability of ambroxol lozenges and commercial tablets in healthy thai volunteers.

    abstract:OBJECTIVE:To compare the bioavailability of two 15mg ambroxol lozenges with a commercial 30mg ambroxol tablet. DESIGN:Open-label, two-way crossover study. METHOD:Each formulation was randomly administered to 20 healthy Thai volunteers (ten male and ten female) with a 1-week washout period between formulations. After ...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.2165/00044011-200323040-00007

    authors: Rojpibulstit M,Kasiwong S,Juthong S,Phadoongsombat N,Faroongsarng D

    更新日期:2003-01-01 00:00:00

  • Hospitalization for severe bacterial infections in children after exposure to NSAIDs: a prospective adverse drug reaction reporting study.

    abstract:BACKGROUND:NSAIDs are widely used to treat fever and pain in children, but their possible role in the progression of some bacterial infections is controversial. OBJECTIVE:This study was performed to analyse reported cases of severe bacterial infection associated with NSAID exposure in children admitted for this reason...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.2165/11532890-000000000-00000

    authors: Leroy S,Marc E,Bavoux F,Tréluyer JM,Gendrel D,Bréart G,Pons G,Chalumeau M

    更新日期:2010-01-01 00:00:00

  • Amlexanox for the treatment of recurrent aphthous ulcers.

    abstract::Recurrent aphthous ulcer (RAU) is the most prevalent oral mucosal disease in humans, estimated to affect between 5% and 50% of the general population. The minor manifestation of the condition is the most common and is characterised by small, shallow, round or oval lesions that are surrounded by a raised erythematous h...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.2165/00044011-200525090-00001

    authors: Bell J

    更新日期:2005-01-01 00:00:00

  • Mecapegfilgrastim in Chemotherapy-Induced Neutropenia: A Profile of Its Use in China.

    abstract::Mecapegfilgrastim (HHPG-19K) is a long-acting pegylated recombinant human granulocyte-colony stimulating factor (rhG-CSF) that is administered subcutaneously as prophylaxis once per chemotherapy cycle as a weight-adjusted dose of 100 µg/kg or as a 6 mg fixed dose. It is approved in China to reduce the incidence of inf...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章,评审

    doi:10.1007/s40261-019-00836-y

    authors: Al-Salama ZT,Keam SJ

    更新日期:2019-10-01 00:00:00

  • First-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer : analysis of the Italian patients enrolled in the SAiL study.

    abstract:BACKGROUND AND OBJECTIVE:First-line bevacizumab-based therapy has been shown to improve outcomes in patients with advanced non-squamous non-small-cell lung cancer (NSCLC). The recent international phase IV SAiL study (a Study of Avastin [bevacizumab] in combination with platinum-containing chemotherapy in patients with...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章,多中心研究

    doi:10.1007/s40261-012-0001-9

    authors: Bearz A,Passalacqua R,Alabiso O,Cinieri S,Gridelli C,Cravesana C,Crinò L

    更新日期:2012-11-01 00:00:00

  • Consumption and distribution of propofol in anaesthesia and intensive care use in Finland.

    abstract:BACKGROUND:Propofol is approved both for anaesthesia and sedation during intensive care. Serious adverse reactions with propofol have recently been reported, but patient exposure to the drug is unknown. OBJECTIVE:To investigate the consumption of propofol in Finnish hospitals and to develop a denominator to estimate p...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.2165/00044011-200323010-00003

    authors: Kokki H,Närhi U

    更新日期:2003-01-01 00:00:00

  • An economic perspective on urinary tract infection: the "costs of resignation".

    abstract:BACKGROUND:Urinary tract infection (UTI) is a leading cause of morbidity in the female population, with high levels of prevalence and recurrence within 6 months. OBJECTIVES:Our objective was to estimate annual costs and health resource utilization by women with UTIs, and the impact on quality of life (QoL) due to lowe...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.1007/s40261-013-0069-x

    authors: Ciani O,Grassi D,Tarricone R

    更新日期:2013-04-01 00:00:00

  • Post-approval Safety Surveillance Study of Golimumab in the Treatment of Rheumatic Disease Using a United States Healthcare Claims Database.

    abstract:BACKGROUND AND OBJECTIVE:Golimumab is a fully human anti-tumor necrosis factor monoclonal antibody approved for the treatment of rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS). This study estimated rates of prespecified outcomes in patients with RA, PsA or AS initiating golimumab ...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.1007/s40261-020-00959-7

    authors: Ziyadeh NJ,Geldhof A,Noël W,Otero-Lobato M,Esslinger S,Chakravarty SD,Wang Y,Seeger JD

    更新日期:2020-11-01 00:00:00

  • Selective serotonin reuptake inhibitor use in primary care: a 5-year naturalistic study.

    abstract:OBJECTIVE:To investigate prescribing trends of selective serotonin reuptake inhibitors (SSRIs) during the course of the Defeat Depression Campaign (1992 to 1996). METHODS:This study utilised cross-sectional data on the prescribing of SSRIs for the treatment of depression from a large primary care database for the 5 co...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.2165/00044011-199816060-00005

    authors: Donoghue J

    更新日期:1998-01-01 00:00:00

  • Pattern of Use and Long-Term Safety of Tyrosine Kinase Inhibitors: A Decade of Real-World Management of Chronic Myeloid Leukemia.

    abstract:BACKGROUND AND OBJECTIVES:First-line treatment of chronic phase (CP) chronic myeloid leukemia (CML) is based on the first-generation tyrosine kinase inhibitor (TKI) imatinib or the second-generation TKIs dasatinib or nilotinib. Thanks to the efficacy of TKIs, CML has switched from a fatal to a 'chronic' pathology, and ...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.1007/s40261-018-0676-7

    authors: Bettiol A,Marconi E,Lombardi N,Crescioli G,Gherlinzoni F,Walley T,Vannacci A,Chinellato A,Giusti P

    更新日期:2018-09-01 00:00:00

  • Topical Lomefloxacin versus Topical Chloramphenicol in the Treatment of Acute Bacterial Conjunctivitis.

    abstract::We performed a prospective, randomised, investigator-masked and parallel-group study to compare topical lomefloxacin 0.3% instilled twice daily with topical chloramphenicol instilled five times daily in the treatment of acute bacterial conjunctivitis. 191 patients (lomefloxacin 96, chloramphenicol 95) were enrolled in...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.2165/00044011-199815040-00001

    authors: Agius-Fernandez A,Patterson A,Fsadni M,Jauch A,Raj PS

    更新日期:1998-01-01 00:00:00

  • Cost effectiveness of fesoterodine and tolterodine for the treatment of overactive bladder with urge urinary incontinence in Spain and Finland.

    abstract:BACKGROUND:Overactive bladder is a prevalent condition worldwide that is associated with a considerable burden, both on the patient and on society. OBJECTIVE:Our objective was to assess the economic value of fesoterodine compared with tolterodine extended release (ER) for the treatment of overactive bladder (OAB) with...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章,评审

    doi:10.1007/s40261-014-0178-1

    authors: Angulo JC,Valpas A,Rejas J,Linden K,Kvasz M,Snedecor SJ

    更新日期:2014-05-01 00:00:00

  • Efficacy of L-carnitine in reducing hyperammonaemia and improving neuropsychological test performance in patients with hepatic cirrhosis : results of a randomised trial.

    abstract:OBJECTIVES:To determine the efficacy of L-carnitine in reducing hyperammonaemia and improving neuropsychological performance in patients with hepatic cirrhosis and subclinical hepatic encephalopathy (SHE). DESIGN:Randomised, parallel group, controlled trial. PATIENTS AND METHODS:The study enrolled 31 patients with he...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.2165/00044011-200222001-00002

    authors: Cecere A,Ciaramella F,Tancredi L,Romano C,Gattoni A

    更新日期:2002-11-01 00:00:00

  • Impact of Herpes Zoster and Post-Herpetic Neuralgia on Health-Related Quality of Life in Japanese Adults Aged 60 Years or Older: Results from a Prospective, Observational Cohort Study.

    abstract:BACKGROUND AND OBJECTIVES:Herpes zoster (HZ) and its most frequent complication, post-herpetic neuralgia (PHN), have been shown to considerably impact quality of life (QoL). This has not yet been demonstrated in Japan. METHODS:QoL in HZ and PHN patients was evaluated using the Zoster Brief Pain Inventory (ZBPI), EuroQ...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章,多中心研究

    doi:10.1007/s40261-017-0581-5

    authors: Mizukami A,Sato K,Adachi K,Matthews S,Holl K,Matsuki T,Kaise T,Curran D

    更新日期:2018-01-01 00:00:00

  • Safety and Plasma Concentrations of a Cyclin-dependent Kinase 9 (CDK9) Inhibitor, FIT039, Administered by a Single Adhesive Skin Patch Applied on Normal Skin and Cutaneous Warts.

    abstract:BACKGROUND:Cutaneous warts are caused by human papilloma virus (HPV) infection. FIT039, a specific inhibitor of CDK9, suppresses the proliferation of DNA viruses in vitro. PURPOSE:We evaluated the safety, plasma concentrations, and efficacy of FIT039 delivered by single application of an adhesive skin patch on normal ...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.1007/s40261-018-0712-7

    authors: Sumi E,Nomura T,Asada R,Uozumi R,Tada H,Amino Y,Sawada T,Yonezawa A,Hagiwara M,Kabashima K

    更新日期:2019-01-01 00:00:00

  • Additive effects of miglitol and anagliptin on insulin-treated type 2 diabetes mellitus: a case study.

    abstract::The aim of this case study was to examine the efficacy of a dipeptidyl peptidase-4 inhibitor (anagliptin) and an α-glucosidase inhibitor (miglitol) when added to ongoing insulin treatment in patients with type 2 diabetes mellitus. Continuous glucose monitoring was performed in four Japanese insulin-treated inpatients ...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.1007/s40261-014-0260-8

    authors: Kishimoto M,Noda M

    更新日期:2015-02-01 00:00:00